Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.72 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195431 | 0.85 | GPR119 (0.74) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL5779093 | 0.85 | GPR119 (0.74) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL15423133 | 0.85 | GPR119 (0.74) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL19450725 | 0.84 | GPR119 (0.72) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL354846 | 0.84 | GPR119 (1.00) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL6118208 | 0.83 | GPR119 (0.67) | GPR119GPR183CNR2LMNAMAPT | |
| SCHEMBL12474791 | 0.83 | GPR119 (0.67) | GPR119GPR183 | |
| SCHEMBL14723499 | 0.82 | GPR119 (0.69) | GPR119GPR183LMNAMAPT | |
| SCHEMBL19059470 | 0.81 | GPR119 (0.68) | GPR119GPR183 | |
| SCHEMBL470543 | 0.81 | GPR119 (0.73) | GPR119GPR183CNR2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| EP-2661438-A2 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | Hanmi Pharm. Co., Ltd. (KR) | 2013-11-13 | — | — | EP | disclosed |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM. CO., LTD (KR) | 2013-10-17 | — | — | US | disclosed |
| CN-103328482-A | New bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM IND CO LTD | 2013-09-25 | — | — | CN | disclosed |
| WO-2012093809-A2 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM CO., LTD. (KR) | 2012-07-12 | — | — | WO | disclosed |
| EP-2399914-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR3 | GPR119 1/4885GPR183 18/4885HRH4 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.